AbbVie Expects $823M Acquired IPR&D And Milestones Expense In Q2 2025, Reducing GAAP And Non-GAAP Diluted EPS By $0.42 To $2.84-$2.88; FY25 Adjusted Diluted EPS Guidance Range, Including The Impact Of Q2 2025 Acquired IPR&D And Milestones Expense, Is $11.67-$11.87

Reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2025 are expected to include acquired IPR&D and milestones expense of $823 million on a pre-tax basis, representing an unfavorable impact of $0.42 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended June 30, 2025 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates.

 

While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2025 previously announced on April 25, 2025 excluded the impact of acquired IPR&D and milestones expense that may be incurred beyond the first quarter of 2025. AbbVie's full-year 2025 adjusted diluted earnings per share guidance range, including the impact of second quarter 2025 acquired IPR&D and milestones expense, is $11.67 - $11.87. AbbVie's second quarter 2025 adjusted diluted earnings per share guidance range, including the impact of second quarter 2025 acquired IPR&D and milestones expense, is